Your browser doesn't support javascript.
loading
A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm.
Fermini, Bernard; Hancox, Jules C; Abi-Gerges, Najah; Bridgland-Taylor, Matthew; Chaudhary, Khuram W; Colatsky, Thomas; Correll, Krystle; Crumb, William; Damiano, Bruce; Erdemli, Gul; Gintant, Gary; Imredy, John; Koerner, John; Kramer, James; Levesque, Paul; Li, Zhihua; Lindqvist, Anders; Obejero-Paz, Carlos A; Rampe, David; Sawada, Kohei; Strauss, David G; Vandenberg, Jamie I.
Afiliación
  • Fermini B; Global Safety Pharmacology, Pfizer Inc., Groton, CT, USA Bernard.fermini@pfizer.com.
  • Hancox JC; School of Physiology and Pharmacology, University of Bristol, Bristol, UK.
  • Abi-Gerges N; Translational Safety, Drug Safety and Metabolism, Innovative Medicines and Early Development, AstraZeneca R&D, Macclesfield, UK AnaBios Corporation, San Diego, CA, USA.
  • Bridgland-Taylor M; Discovery Sciences, Innovative Medicines and Early Development, AstraZeneca R&D, Macclesfield, UK.
  • Chaudhary KW; Safety Assessment, GlaxoSmithKline, King of Prussia, PA, USA.
  • Colatsky T; Division of Applied Regulatory Science, CDER, US Food and Drug Administration, Silver Spring, MD, USA.
  • Correll K; Safety Pharmacology Society, Reston, VA, USA.
  • Crumb W; Zenas Technologies LLC, New Orleans, LA, USA.
  • Damiano B; Global Safety Pharmacology, Discovery Sciences, Janssen Research & Development LLC, Spring House, PA, USA.
  • Erdemli G; Center for Proteomic Chemistry, Novartis Institutes for BioMedical Research, Inc, Cambridge, MA, USA.
  • Gintant G; Department of Integrative Pharmacology, Integrated Sciences & Technology, AbbVie, North Chicago, IL, USA.
  • Imredy J; Department of Safety Assessment, Merck & Co, Kenilworth, NJ, USA.
  • Koerner J; Division of Cardiovascular and Renal Products, CDER, U.S. Food and Drug Administration, Silver Spring, MD, USA.
  • Kramer J; ChanTest, A Charles River Company, Cleveland, OH, USA.
  • Levesque P; Bristol Myers Squibb Research & Development, Princeton, NJ, USA.
  • Li Z; Division of Applied Regulatory Science, CDER, US Food and Drug Administration, Silver Spring, MD, USA.
  • Lindqvist A; Biolin Scientific, Ballerup, DK.
  • Obejero-Paz CA; ChanTest, A Charles River Company, Cleveland, OH, USA.
  • Rampe D; Preclinical Safety, Sanofi, Bridgewater, NJ, USA.
  • Sawada K; Global Cardiovascular Assessment, Eisai Co., Ltd., Ibaraki, Japan.
  • Strauss DG; Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, MD, USA.
  • Vandenberg JI; Victor Chang Cardiac Research Institute, St Vincent's Clinical School, University of NSW, Darlinghurst, NSW, Australia.
J Biomol Screen ; 21(1): 1-11, 2016 Jan.
Article en En | MEDLINE | ID: mdl-26170255
For the past decade, cardiac safety screening to evaluate the propensity of drugs to produce QT interval prolongation and Torsades de Pointes (TdP) arrhythmia has been conducted according to ICH S7B and ICH E14 guidelines. Central to the existing approach are hERG channel assays and in vivo QT measurements. Although effective, the present paradigm carries a risk of unnecessary compound attrition and high cost, especially when considering costly thorough QT (TQT) studies conducted later in drug development. The C: omprehensive I: n Vitro P: roarrhythmia A: ssay (CiPA) initiative is a public-private collaboration with the aim of updating the existing cardiac safety testing paradigm to better evaluate arrhythmia risk and remove the need for TQT studies. It is hoped that CiPA will produce a standardized ion channel assay approach, incorporating defined tests against major cardiac ion channels, the results of which then inform evaluation of proarrhythmic actions in silico, using human ventricular action potential reconstructions. Results are then to be confirmed using human (stem cell-derived) cardiomyocytes. This perspective article reviews the rationale, progress of, and challenges for the CiPA initiative, if this new paradigm is to replace existing practice and, in time, lead to improved and widely accepted cardiac safety testing guidelines.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Arritmias Cardíacas / Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos / Corazón Tipo de estudio: Diagnostic_studies / Guideline Límite: Animals / Humans Idioma: En Revista: J Biomol Screen Asunto de la revista: BIOLOGIA MOLECULAR Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Arritmias Cardíacas / Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos / Corazón Tipo de estudio: Diagnostic_studies / Guideline Límite: Animals / Humans Idioma: En Revista: J Biomol Screen Asunto de la revista: BIOLOGIA MOLECULAR Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos